Product NDC: | 64406-008 |
Proprietary Name: | TYSABRI |
Non Proprietary Name: | natalizumab |
Active Ingredient(s): | 300 mg/15mL & nbsp; natalizumab |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 64406-008 |
Labeler Name: | Biogen Idec Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA125104 |
Marketing Category: | BLA |
Start Marketing Date: | 20041123 |
Package NDC: | 64406-008-01 |
Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (64406-008-01) > 15 mL in 1 VIAL, SINGLE-USE |
NDC Code | 64406-008-01 |
Proprietary Name | TYSABRI |
Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (64406-008-01) > 15 mL in 1 VIAL, SINGLE-USE |
Product NDC | 64406-008 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | natalizumab |
Dosage Form Name | INJECTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20041123 |
Marketing Category Name | BLA |
Labeler Name | Biogen Idec Inc. |
Substance Name | NATALIZUMAB |
Strength Number | 300 |
Strength Unit | mg/15mL |
Pharmaceutical Classes | Integrin Receptor Antagonist [EPC],Integrin Receptor Antagonists [MoA] |